The Journal of Clinical Investigation’s Post

Advancing Prostate Cancer Diagnosis: [99mTc]Tc-PSMA SPECT/CT Accurate prostate cancer diagnosis is critical, yet limited access to [68Ga]Ga-PSMA PET/CT poses challenges. Recent findings show that [99mTc]Tc-PSMA SPECT/CT offers promising diagnostic accuracy, with 89% sensitivity and 92% specificity. This alternative imaging tool could be particularly valuable in regions with limited PET/CT availability, warranting further validation in larger patient cohorts. #ProstateCancer #MedicalImaging #NuclearMedicine #HealthcareInnovation #SPECTCT #PSMA

Source: Sensors (Basel, Switzerland) This study investigates the potential of using negatively charged glycans attached to exosomes as liquid biopsy markers for early prostate cancer diagnosis. The researchers characterize exosomes produced by benign and carcinoma cell lines, comparing their properties and surface receptors. They find that cancerous exosomes are smaller, produced at higher concentrations, and have a more negative charge. The study also identifies specific glycans present on the surface of the exosomes, with different types being more abundant in cancerous and control exosomes. The results suggest that glycoprofiling exosomes could be an effective method for liquid biopsy diagnosis of prostate cancer.

Are you interested in learning about the difference between Alpha and Beta emitters in prostate cancer radiopharmaceuticals? Then check out this UroToday + GU OncToday interview with Alan Bryce, who discusses the decision-making process when choosing between radium-223 and lutetium-177. During the discussion, Dr. Bryce highlights the differences in cellular impact between Alpha and Beta particles, including their energy transfer and travel distance, affecting dose delivery and toxicity. https://lnkd.in/geU5Z7Uu #nuclearmedicine #radiopharmaceuticals #cancertreatment

Very excited to share that our article is now published in Lancet Oncology; a phase 1/2 first-in-human clinical trial utilizing immunoPET-CT imaging to visualize DLL3 expression in patients with small-cell lung cancer (SCLC) and Neuroendocrine Prostate Cancer (NEPC). Thank you to all the patients for their participation in the study. I also want to thank my collaborators and mentors for all their support. https://lnkd.in/exN6MKU4

Additional data from the phase 1/2 COBRA study highlight the ability of 64Cu-SAR-bisPSMA to detect prostate cancer lesions less than 5 mm in size. https://lnkd.in/ewcXvMnD

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study https://lnkd.in/dqWzvdvE

Results of a meta-analysis support the use of ketoconazole for patients with previously treated castration-resistant prostate cancer who experience a persistent rise in prostate specific-antigen (PSA) levels. https://brnw.ch/21wKSaB

✅Prostate cells gradually develop resistance against Docetaxel, a chemotherapeutic drug commonly used for advanced prostate cancer. ✅Cholinergic muscarinic M1 receptor (CHRM1) expression in prostate cells is the major driver of this resistance. ✅Researchers, inactivated CHRM1 using Dicyclomine (a CHRM1-selective antagonist), translating to a reversal in Docetaxel resistance in prostate cells.

#PaperoftheDay: "Unveiling the non-canonical functions of EZH2 in prostate cancer" DOI ⬇️ https://lnkd.in/e9mScn9x #prostatecancer #cancer #research #oa #peerreview #publishing

68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial https://lnkd.in/dgwnZaNb